Whether enhanced RAF kinase activity influences these later changes is an uncertain but important question when considering BRAF and RAF kinases as therapeutic targets for patients with undifferentiated forms of thyroid cancer. The gene discussed is BRAF; the disease is thyroid gland carcinoma.